4DMedical, a leader in advanced respiratory imaging technology, has secured a contract with the United States Department of Defence (DoD) to pilot its CT Ventilation-Perfusion (CT:VQ) technology.
The program will assess lung health in a fixed cohort of 80 active-duty personnel and builds on the success of 4DMedical’s previous collaboration with the DoD involving its CT Lung Ventilation Analysis Software (CT LVAS), the company said in an ASX announcement.
The DoD operates one of the largest healthcare systems in the world, serving over 9.6 million active-duty service members, their families, and retirees.
This new agreement highlights the DoD’s recognition of 4DMedical’s capability to deliver advanced health insights, particularly for personnel exposed to hazardous environments and deployment-related lung diseases.
Under the contract, 4DMedical will provide a fixed number of scan analysis reports using its CT:VQ platform on full commercial terms.
The technology offers clinicians a noninvasive, detailed view of both ventilation and perfusion within the lungs, eliminating the need for radioactive isotopes used in traditional Nuclear VQ scans.
This innovation is expected to enable earlier detection and monitoring of pulmonary conditions such as COPD and chronic thromboembolic hypertension, improving patient outcomes and reducing healthcare costs.
4DMedical’s Founder, MD, and CEO Andreas Fouras expressed gratitude for the DoD’s continued interest in the company’s technology.
He noted that the collaboration underscores the value of 4DMedical’s imaging solutions in addressing the unique health challenges of military personnel.
Fouras highlighted that the pilot program represents a significant milestone in the company’s market adoption strategy, reinforcing its competitive edge even prior to FDA clearance of CT:VQ.
The evaluation with the DoD positions 4DMedical to expand its opportunities within the Military Health System and the Department of Veterans Affairs while advancing its goal of disrupting the billion-dollar respiratory diagnostics market.
